


Review

Gender-Specific Degeneration of Dementia-Related Subcortical Structures Throughout the Lifespan

László Vecsei, Anikó Mészáros, Csilla Horváth, Anett Kizlák

View metadata, citation and similar papers at core.ac.uk

brought to you by  CORE

provided by Repository of the Academy's Library

^aDepartment of Neurology, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, University of Szeged, Szeged, Hungary

^bDepartment of Psychiatry, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, University of Szeged, Szeged, Hungary

^cMTA-SZTE Neuroscience Research Group, Szeged, Hungary

^dInternational Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic

Accepted 21 September 2016

Abstract. Age-related changes in brain structure are a question of interest to a broad field of research. Structural decline has been consistently, but not unambiguously, linked to functional consequences, including cognitive impairment and dementia. One of the areas considered of crucial importance throughout this process is the medial temporal lobe, and primarily the hippocampal region. Gender also has a considerable effect on volume deterioration of subcortical grey matter (GM) structures, such as the hippocampus. The influence of age \times gender interaction on disproportionate GM volume changes might be mediated by hormonal effects on the brain. Hippocampal volume loss appears to become accelerated in the postmenopausal period. This decline might have significant influences on neuroplasticity in the CA1 region of the hippocampus highly vulnerable to pathological influences. Additionally, menopause has been associated with critical pathobiochemical changes involved in neurodegeneration. The micro- and macrostructural alterations and consequent functional deterioration of critical hippocampal regions might result in clinical cognitive impairment—especially if there already is a decline in the cognitive reserve capacity. Several lines of potential vulnerability factors appear to interact in the menopausal period eventually leading to cognitive decline, mild cognitive impairment, or Alzheimer's disease. This focused review aims to delineate the influence of unmodifiable risk factors of neurodegenerative processes, i.e., age and gender, on critical subcortical GM structures in the light of brain derived estrogen effects. The menopausal period appears to be of key importance for the risk of cognitive decline representing a time of special vulnerability for molecular, structural, and functional influences and offering only a narrow window for potential protective effects.

Keywords: Aging, cognitive decline, gender, hippocampus CA1 region, subcortical grey matter

INTRODUCTION

Age-related changes in brain structure are a question of interest to a number of different fields of research including neuroendocrinology, neurobiology, and neuroimaging, to just name a few. The

*Correspondence to: László Vecsei, MD, PhD, DSc, Department of Neurology, University of Szeged, H-6725 Szeged, Semmelweis u. 6, Hungary. Tel.: +36 62 545 351 / 545 348; Fax: +36 62 545 597; E-mail: vecsei.laszlo@med.u-szeged.hu.

growing body of research evidence has linked structural alterations to certain functional and clinical manifestations, including dementia-related disorders. Dementia has become a major health and public concern worldwide with an increasing prevalence in the aged population. The most common cause of dementia in the general population above 60 years of age is Alzheimer's disease (AD) [1]. AD is characterized by progressive behavioral, affective, social, and cognitive impairment [2]. The neuropathological changes presumed to stand behind the functional impairment are primarily the amyloid depositions and the neurofibrillary tangles [3, 4]. These histopathological alterations have been described in several brain regions involving widespread frontal, parietal, and temporal cortical and subcortical structures. Among these, medial temporal subcortical structures are typically considered the most commonly emphasized areas affected [5]. The most important risk factor of developing AD that cannot be influenced is age itself [6]. The most recent systematic review and meta-analysis on prevalence and incidence of dementia, and dementia due to AD found that increasing age was significantly associated with increasing prevalence and incidence rates of dementia [7] and AD [8]. Thus it appears crucial to understand the age-related changes occurring in brain structures of potential key importance. Large sample epidemiological studies show that women have a significantly higher risk of developing AD for various reasons (e.g., longer lifespan) [9–11]. Interestingly, incidence rates appear to show an age-dependent relationship between sex and likelihood of developing AD. Incidence of AD has been reported to increase with age for both sexes until about 85–90 years but to continue to increase among women only [12]. Therefore, gender is also considered a crucial unmodifiable factor in AD pathology with clear differences in structural and functional decline of specific brain areas.

This review will be focusing on age and gender dependent changes in grey matter (GM) micro- and macrostructures—and especially subcortical GM formations—and related cognitive alterations as a functional representation in AD pathology.

GREY MATTER ALTERATIONS IDENTIFIED IN AD

A number of studies have addressed the neuroanatomical changes in the background of clinical symptoms presenting in AD. A recent large sample

meta-analysis has used anatomic likelihood estimation aiming to identify more robust and consistent alterations [5]. GM atrophy has been found to primarily affect bilateral medial temporal lobe (MTL) structures, involving the amygdala, hippocampus, parahippocampal gyrus, uncus, and entorhinal cortex, as well as the thalamus, caudate, and cingulate cortices [13]. Strikingly, one significant cluster in the left MTL has been identified as a potential anatomical marker for AD development and progression. A robust GM loss has frequently been documented in regions of the MTL bilaterally [14, 15]. Furthermore, the microstructure of the white matter fibers in the close vicinity of the mediotemporal structures are also affected by the disease [16]. Hypometabolism as measured by PET studies and hypoactivation as revealed by functional MRI have also been reported [17]. Disrupted functional connectivity in these regions further supports the critical role of MTL structures in the pathophysiology of AD [18, 19]. A main question of debate remains as to what extent these changes reflect the course of the disease. Research evidence indicates that relevant alterations are present primarily in areas of the MTL several years before the clinical signs of AD [20]. Moreover, morphological abnormalities and atrophy have been detected in the left MTL specifically as the most consistent structure to predict conversion from mild cognitive impairment (MCI) to AD [21]. Thus, based on the pattern of structural atrophy, the left MTL has been suggested as a marker of disease progression in AD [5] (for a summary of referenced findings please see Table 1).

AGE-RELATED CHANGES OF RELEVANT GM STRUCTURES

A great body of research evidence confirms that aging is associated with decrease in total whole-brain volume [22–24], overall GM and white matter (WM) volume [25–29], as well as cortical thickness [30]. It seems evident to state that, parallel to total brain volume, the volume of subcortical brain structures in general decreases with age. However, evidence indicates that the changes are very different in specific brain areas [31, 32]. Even studies reporting no overall significant effect of aging on WM volume did reveal a decline with age in some areas [26, 33].

In order to understand the relevance of the structural loss, we have to decipher their complex neurobiological background and their effect

Table 1

Age- and gender-related changes of medial temporal lobe, with the major focus on the hippocampus

Golomb et al., [160] Murphy et al., [50]	Size of hippocampal formation predicts longitudinal alterations of performance on memory tests. Larger age-related total GM volume loss and atrophy in frontal and temporal areas in males than in females, Greater atrophy in females than in males in hippocampus and parietal cortices. Hemispheric metabolic asymmetry in temporal and parietal cortices, Broca's area, thalamus, and also in hippocampus.
Raz et al., [43]	Largest age-related decline: volume of the prefrontal cortices. Slighter age-related alterations: volume of the fusiform gyri, inferior temporal, superior parietal areas. Weak effects of age on hippocampus and postcentral gyrus. Larger total brain volume and the hippocampus in males than in females.
Jack et al., [161]	Annual decline in hippocampal volume, increase in temporal horn volume was identified in the elderly. 2.5 times greater rates in patients with AD than in age- and gender-matched controls.
Xu et al., [60]	Larger atrophy with aging in right frontal lobe posteriorly in males compared to females. Age-related atrophy in right temporal lobe medially, in parietal cortices, cerebellum + left basal ganglia in males, but not in females. Smaller left thalamus, parietal, occipital cortices + cerebellum volume compared to the right hemisphere. No age- and gender-related difference in this asymmetry.
Good, et al., [26]	Linear global GM volume loss with age, steeper decline in men. Accelerated loss bilaterally in the insula, superior parietal gyrus, central sulcus + cingulum. Little or no age effect in amygdala, hippocampus + entorhinal cortex.
Ge et al., [25]	Constant GM volume loss, linearly with age throughout adulthood, whereas delayed WM volume loss until midlife. No effect of sex.
Scahill et al., [24]	Acceleration in atrophy with age in all analyses, prominently after the age of 70, particularly in the ventricles and in the hippocampus.
Wang et al., [162]	Distinct patterns of hippocampal shape alteration with age, different patterns of hippocampal volume loss may distinguish mild dementia from healthy aging.
Sullivan et al., [52]	Linear thalamic volume loss with age in a similar pace in males and females, whereas more steep cortical GM volume decline during aging in men than in women.
Fleisher et al., [80]	Greater deleterious effect of APOE*E4 genotype status on gross hippocampal pathology and memory functions in women as compared to men.
Lemaitre et al., [55]	Between the ages of 63 and 75 years, largest GM atrophy in primary cortices + in angular gyri, superior parietal gyri, orbitofrontal cortex + in hippocampus. No sex \times age interaction.
Ahsan et al., [42] Smith et al., [29]	Larger left caudate, nucleus accumbens + putamen, and larger globus pallidus in men. Relative regional differences in GM volume frontal, parietal + temporal cortices, no volume loss in medial temporal lobe and in posterior cingulate. No gender effects.
Sowell et al., [30]	Thicker right inferior parietal + posterior temporal cortices in females. Gender differences in these areas are detectable from late childhood and are maintained throughout life.
Curiati et al., [35]	Selective focus of accelerated GM reduction only in men, including temporal neocortices, prefrontal cortices, and medial temporal areas.
Neufang et al., [65]	Larger GM volumes of left amygdala in males, larger right striatal GM volumes and hippocampal GM volumes bilaterally in females. Independently of gender, volumes of amygdala and hippocampus are associated with levels of circulating testosterone.
Ostby et al., [36]	From childhood until adulthood: non-linear decrease in GM in cerebral cortex, linear decrease in caudate, putamen, pallidum, nucleus accumbens, and cerebellum. Small, non-linear increase in amygdala and hippocampal GM volume.
Ystad et al., [163]	Hippocampal volumes are important predictors for memory function in elderly women. Hemispheric asymmetry in hippocampal volumes during aging. In females, volume of left hippocampus has predictive value. Gender and left hippocampal volume may predict verbal memory performance in healthy elderly.
Erickson et al., [82] Fjell and Walhovd, 2010 [38]	Limited time window for hormone replacement therapy to positively influence hippocampal volume. Heterogeneous pattern in the atrophy of specific brain areas during aging: largest shrinking in frontal and temporal cortices + in putamen, thalamus, and nucleus accumbens.
Mukai et al., [77] Goto et al., [83]	Important role of hippocampus-derived estradiol in the modulation of synaptic plasticity. Reduced GM volume in bilateral hippocampus in females in their fifties (most of them experiencing menopause) compared to females in their forties (most of them not experiencing menopause). → Menopause may correlate with reduction of hippocampal volume.
Skup et al., [45]	Different patterns of decline with age in males and females in AD group and MCI group compared to healthy controls in precuneus and caudate nucleus bilaterally, right entorhinal gyrus, thalamus bilaterally, left insula, and also in right amygdala.
Takahashi et al., [51]	More retained GM concentrations in females during aging in inferior frontal gyri bilaterally, cingulate gyrus anteriorly, hypothalamus and in medial thalamus.

(Continued)

Table 1
(Continued)

Devanand et al., [164]	Differences in volumes of hippocampus, entorhinal cortex, and parahippocampal gyrus between MCI and healthy controls. In patients converting from healthy to MCI: larger atrophy in the head of hippocampus, specifically in CA1 and subiculum, in entorhinal cortex, especially in bilateral pole of EC.
Borghesani et al., [165]	Improvement of midlife memory positively correlates with larger hippocampal volume in the elderly, compared to those who had decline or no change in their episodic memory in their midlife.
Ooishi et al., [78]	Crucial role of hippocampus-derived estradiol, T, and DHT in modulating synaptic plasticity.
Rijpkema et al., [53]	No gender difference in caudate nucleus and nucleus accumbens. Larger globus pallidus and putamen volume.
Spencer-Segal et al., [79]	In females, important role of estrogen receptor signaling in hormone's influence regarding hippocampal synaptic plasticity.
Fjell et al., [34]	Faster estimated decline in the elderly in hippocampus.
Taki et al., [166]	Positive correlations between yearly regional GM volume alterations and age: temporal pole bilaterally, caudate nucleus, insula, hippocampus. Negative correlations between age and changes in cingulate gyri bilaterally + cerebellum. Age × gender interaction between annual ratio of regional GM volume change in hippocampus bilaterally.
Crivello et al., [167]	Higher GM decline in females compared to males (persistent throughout age ranges) Hippocampus: similarly accelerated decline with age in males and females.
Li et al., [58]	Age-related atrophy in basal ganglia and thalamus. Hippocampus atrophy in males only, and no decline in the amygdala.
Perlaki et al., [57]	No sexual dimorphism in the size of hippocampus.
Kiraly et al., [56]	Larger hippocampus volume in females. Age-related decrease of caudate nucleus, putamen and thalamic volumes in males. Thalamic volume loss in females. Faster decrease in total GM volume in males as compared to females.

on functionality. Fjell and his co-workers have done tremendous work in an effort to characterize cross-sectional and longitudinal changes in brain aging and to compare healthy normal aging to pathological alterations (i.e., the Alzheimer Disease Neuroimaging Initiative) [34]. Fjell et al. have used a nonparametric smoothing spline approach to assess age trajectories of anatomical structures in a large sample of healthy adults. Cross-sectional as well as longitudinal, follow-up data has been analyzed identifying certain critical age periods. These critical ages would account for a more significant rate of change within the estimated range of volume loss. Latter has been described for total brain volume with a stronger correlation above the age of 60, as well as for the cerebral cortex, and, interestingly the pallidum, with the age of around 25 years correlating most with structural decline. A linear reduction with age has been identified for a number of subcortical structures, i.e., the amygdala, nucleus accumbens, putamen, and the thalamus, also supported by several previous findings [31, 35]. The hippocampus has been previously characterized by a nonlinear pattern of estimated change through adulthood. This might be explained by a prolonged phase of development [36], a longer stable period and, critically, an accelerated volume loss starting around the age

of 50 and an even more robust negative relationship above 60 [37–39]. Indeed, in the longitudinal analysis, the hippocampus showed the fastest rate of volume reduction (−0.83% per year) among subcortical structures [34]. Changes in brain volume constitute a truly dynamic process with a great number of potential influencing factors, which should be ideally monitored by using longitudinal approaches with a high density of assessments. Nevertheless, more complex and sophisticated methods of analysis as well as large volume data could yield more insight into targeted questions [40].

Another highly dynamic process throughout the human lifespan is considered the interaction with and accommodation of constant endogenous and exogenous influences. The view of lifespan trajectories of change in brain structure and function might serve as a base of understanding vulnerability to certain age-related disorders such as MCI and AD. It might be crucial to emphasize the potential significance of life course effects which, in a complex interaction, will eventually separate dementia and cognitive decline from normal aging-related mechanisms. However, it also appears that the relationship between different exogenous and endogenous events and their impact on brain structure and function varies in importance in the light of the time of their occurrence [41].

GENDER-RELATED CHANGES OF RELEVANT GM STRUCTURES

Sexual dimorphism of the human brain anatomy has gained increasing interest, with subcortical GM structures also being investigated more widely [42].

A number of studies have addressed the combined effects of age and gender on human brain structures. A more profound decline in GM volume has been described in males [33, 43, 44]. However, in patients with MCI and AD, GM volume has been found to decline faster in females as compared to males supporting the evidence of faster progression from MCI to AD [45]. This might be related to the main difference in brain anatomy between sexes, i.e., brain size. A larger brain might well have a greater reserve capacity to withstand pathology at the same level of functionality and cognitive abilities [46]. This has also been underlined by autopsy studies reporting women to have significantly higher odds of a clinical diagnosis of AD at the same level of neuronal pathology [47].

The effect of gender on the volume of these structures might be crucial, considering that basal ganglia possess a high density of sex steroid receptors [48]. However, neuroimaging results on the gender dependent volume of subcortical GM are somewhat contradictory. Some studies reported larger volumes of the caudate nuclei [49], hippocampus [50], and thalamus in females [51], while others had opposing results [52, 53]. The amygdala [54], pallidum, and the putamen [53] have been consistently found to be larger in males. Thus, research evidence appears inconsistent especially considering the subcortical GM structure [55]. This might also be due to the method of analysis, considering the difficulty to delineate subcortical GM using conventional voxel based morphometric methods. Our research group has applied a deformable surface model based segmentation approach to address volumetric alterations especially in regions with low tissue contrast [56]. While age, gender, and head size (intracranial volume) are the most commonly included 'nuisance' variables when performing neuroimaging analysis, studies vary as to which of these variables are included and which method is used for correction [57]. These factors might widely account for the great variability in the results. Accounting for skull size significantly influences results when it comes to GM volume and it might be of even greater importance when considering differences between males

and females. Our results revealed larger cortical and subcortical GM volume for females as a result of correction for total intracranial volume in a study involving 103 participants in the age range of 21–58 years. The volume of the hippocampus was found significantly larger in the female group as compared to males. We also detected a significant effect of hemisphere in the male group only, with larger volumes of the right caudate and the left thalamus as compared to their contralateral structures.

Interestingly, we also found an age-dependent decrease in the volume of cortical as well as subcortical GM. Latter remained significant after correction for skull size in the caudate, putamen, and thalamus bilaterally for males and the thalamus bilaterally for females. Within the age range of 21 to 58 years, we found a linear decrease in GM volume with aging. Strikingly, this process proved to occur at a faster pace in males. Converging research evidence emphasizes the importance of considering age and sex interaction effects on the volumetric decline of subcortical structures. Li and his colleagues found this to be of key relevance for the hippocampus specifically, showing a linear negative correlation with age for males only [58]. Strikingly, for females, the pace of hippocampal volume decline has been found to occur at an even slower pace than whole brain volume loss. In contrast with this, a strong effect of aging on basal ganglia and thalamus volume changes has been observed primarily for females. The authors link these results to functional consequences involving predominantly psychomotor performance especially at later ages [59–61]. However, a number of studies did not find a significant effect of gender on cognitive performance or decline with age [62, 63]. While directly linking functional aspects to structural changes in brain anatomy might not be equivocal, elucidating effects of age \times sex interaction on specific subcortical GM regions might well serve the investigation of related psychopathological alterations, such as MCI or AD.

The background of the disproportionate GM volume changes has not yet been elucidated, but the changes in hormone levels and the consequent sensitivity of the brain to hormonal effects are most certainly involved [64]. Sex hormones have been found to critically influence regional maturation of subcortical GM structures, e.g., higher circulating testosterone levels correlated positively with amygdala volume and negatively with hippocampal volume [65]. Estrogen among androgens has gained significant interest for its crucial role

287 during brain development. Females with endogenous
288 estrogen deficiency have been found to have dis-
289 proportionately reduced hippocampal volumes and
290 increased amygdala volume as compared to age-
291 matched controls [66]. This might be related to the
292 complex distribution of estrogen receptors through-
293 out the brain. Distinct estrogen receptor subtypes
294 have been identified in nearly all cell types of the
295 central nervous system, and importantly, in brain
296 regions typically associated with cognitive func-
297 tion such as memory and affective processing, e.g.,
298 the amygdala and the hippocampus [67]. Strikingly,
299 the estrogen-related volume deficiency evidenced by
300 structural neuroimaging has also been associated
301 with functional consequences revealed by cognitive
302 assessment [68].

303 Epidemiological results support the notion that
304 age-related loss of steroid hormones is associ-
305 ated with an increasing risk to develop AD [69].
306 Above this, AD prevalence is higher in post-
307 menopausal women as compared to age-matched
308 men—not explained by the generally higher life
309 expectancy for females [70, 71]. The crucial role of
310 estrogen is supported by several lines of evidence,
311 with early menopause having been associated with
312 an increased prevalence of dementia [72]. Estro-
313 gen has been found to modulate neurogenesis and
314 activation of new neurons in response to targeted cog-
315 nitive demands in the hippocampus [73, 74]. This
316 might be mostly dependent on brain derived estradi-
317 ol concentration [75], suggesting the importance
318 of neuronal, and especially hippocampal, estrogen
319 production [76]. Estrogen has a potent effect on
320 inducing neurogenesis, neuronal morphology, and
321 plasticity in specific areas of the hippocampus,
322 such as the CA1 region and the dentate gyrus [74,
323 77–79]. An association between estrogen deficiency
324 and hippocampal volume loss in females with clini-
325 cally diagnosed MCI [80] might well serve as a
326 potential common course leading to AD. However,
327 there might be another crucial aspect, which should
328 be emphasized when considering neuronal estro-
329 gen related hippocampus structure and function. A
330 significant sex hormone cycle related effect on spe-
331 cific cognitive performance has only been found
332 during initial testing and disappeared with repeated
333 examinations of the same parameter, controlling for
334 other confounding factors [81]. This occurred dur-
335 ing an 8-week long testing period, which raises
336 interesting questions about a life course perspec-
337 tive of hippocampus-related cognitive performance
338 and the risks of consequent dementia. Furthermore,

339 hormone treatment effects on the hippocampus
340 in post menopause detected a limited window of
341 opportunity to influence hippocampal volume. How-
342 ever, the larger hippocampal volumes associated
343 with hormone treatment initiated at the time of
344 menopause did not translate to improved cognitive
345 performance [82].

346 Hippocampal volume loss appears to become
347 accelerated in the postmenopausal period [83],
348 which, associated with brain estrogen production
349 decline, might be due to a significant reduction in neu-
350 ronal plasticity primarily in the CA1 region. While
351 postmenopausal hormone replacement therapy might
352 spare the total hippocampal volume in a limited win-
353 dow of action, this might not be effective on the key
354 areas of neuroproliferation. Consecutively, cognitive
355 performance is not affected beneficially, eventually
356 leading to the development of MCI or AD, due to
357 the impaired cognitive reserve abilities influenced by
358 several other factors (Fig. 1).

359 **FUNCTIONAL CONSEQUENCES OF GM** 360 **CHANGES RELEVANT FOR DEMENTIA** 361 **OCCURANCE**

362 Above the structural differences, there is increas-
363 ing evidence for the functional sexual dimorphism of
364 subcortical structures. Hippocampus-related memory
365 functions are differently affected by stress in males
366 and females [84]. Peripartum hormonal changes are
367 known to modulate the hippocampal function [85]. In
368 addition to gender effects, recent evidence supports
369 the influence of brain hemisphere showing lateral-
370 ization of structure-function relationships, as well as
371 more specific relationships between individual struc-
372 tures (e.g., left hippocampus) and functions relevant
373 to particular aptitudes (e.g., vocabulary) [86]. Numer-
374 ous differences between the cognitive patterns of the
375 two sexes have been reported [87]. Estrogen and
376 testosterone appear to play a significant and contin-
377 uous role in cognition throughout the lifespan [58].
378 In puberty, adolescents who mature later have better
379 visuospatial skills than those who mature earlier [88].
380 Furthermore, a longer reproductive period is associ-
381 ated with higher levels of verbal fluency later during
382 adulthood [89]. In adulthood, certain differences
383 between male and female cognitive features are well
384 known, e.g., higher performance on visuospatial tasks
385 in males and female advantage in verbal skills [90].
386 This characteristic pattern of different cognitive abil-
387 ities appears to persist later in life [91]. Interestingly,




Fig. 1. According to major communication pathways of the hippocampal circuit multisensory input information enters primarily the entorhinal cortex (EC) then projecting towards the dentate gyrus (DG) and the CA3. Pyramidal cells of the CA3 send their axons to the CA1, which then projects to deep layers of the EC and sends the selected information along the output paths of the hippocampus. Additionally, feedback is being provided to the EC. The postmenopausal period and related estrogen loss might be associated with changes in the neuroplastic capacity of especially vulnerable regions of the hippocampus, such as the CA1 region. This region is rich in brain derived estrogen receptors and represents a key area for estrogen related neuronal manifestations. Molecular and pathobiochemical alterations might be present in the background of this deterioration, i.e., mitochondria-related inflammatory, oxidative effects. As a consequence, the selection of relevant information might become impaired or completely altered. In addition, the feedback source of the EC representing the major multisensory input area also becomes disturbed or even absent. In the presence of an impaired cognitive reserve capacity related to several previous internal and external factors, this might be an especially vulnerable time window for hippocampal structural and functional decline. This could result in an accelerated volume loss of the hippocampus and presumably, a consequent significant cognitive decline.

388 cognitive skills of women tend to decline slower
389 than those of men [92]. Estrogen has been
390 suggested as a protective factor against dementia
391 through facilitating neurogenesis in the hippocam-
392 pus and thus enhancing hippocampus-related spatial
393 learning and aspects of memory [74].

394 Distinguished patterns of cognitive skills were con-
395 firmed not only in healthy aging, but also in patients
396 with AD. Assessing AD patient's verbal skills, a
397 meta-analysis revealed a difference in naming tasks
398 and semantic fluency with lower performance in
399 women [93]. As to visuospatial skills, no significant
400 difference was found between women and men with
401 AD [94]. Based on another meta-analysis assessing
402 global dementia severity in men and women, it was
403 found that women reached a significantly lower score
404 compared to men with AD [95].

405 Apart from the individual's sex and its hormonal
406 influences on cognition through the lifespan, other
407 contributing factors might enhance or prevent cogni-
408 tive decline and developing AD. According to a recent
409 cohort study, lower performance in school during
410 childhood may increase the risk for cognitive decline
411 in later life [96]. Greater midlife stress is associated
412 with a higher risk to develop dementia, especially
413 AD among women [97]. Strongly negative life events
414 such as losing a close relative can also increase vul-
415 nerability to enhance cognitive decline along with
416 depression; however, milder but chronic stress factors
417 may even stimulate cognitive functioning [98].

418 Brain areas typically affected in MCI and AD
419 have a specific hierarchical order in which they
420 become altered during the course of the disease based
421 on Braak and Braak's neuropathological model [3].
422 According to this model, the first lesions can be
423 detected in the MTL, including the hippocampus,
424 parahippocampus, and crucial areas of the limbic
425 circle, e.g., the amygdala, then in several areas of
426 the temporal lobe, followed by other regions of the
427 neocortex. The affected structures have their distinct
428 roles in cognition; however, they contribute alto-
429 gether to the characteristic clinical manifestation of
430 AD. As an example of key importance, higher visual
431 perception, including identification and recognition
432 of faces and landmarks, as well as recognition of
433 facial emotions, is dependent on the medial temporal
434 lobe structures [99]. The impairment of these abili-
435 ties might have an impact on behavioral disturbances
436 in early AD and might even serve early identification
437 of AD [100].

438 Being a key structure of the MTL and its memory
439 network, the integrity of the hippocampus is required

440 not only in episodic and semantic memory, but also
441 in spatial information processing and manipulation
442 [101]. The reduced ability to retain new information is
443 one of the earliest core features of dementia and con-
444 stitutes a heavy burden on the daily life of patients and
445 caregivers [102]. A significant correlation of reduced
446 hippocampal volume combined with higher levels
447 of cortisol and performance on auditory and ver-
448 bal memory subtests of the Wechsler's Intelligence
449 Scale and Block Design tests measuring visuospat-
450 tial skills has also been reported [103]. A recent
451 study describes decreased thickness of the hippocam-
452 pal GM formation in AD as compared to healthy
453 individuals or patients with MCI [104]. Considering
454 that scores on the Mini-Mental State Examination
455 (MMSE) and the Alzheimer's Disease Assessment
456 Scale-Cognition (ADAS-Cog) correlate with base-
457 line entorhinal cortex thickness, its atrophy might
458 be a predictor of subsequent cognitive impairment.
459 The atrophy of hippocampal areas has been asso-
460 ciated with more severe deficits in several aspects
461 memory (especially episodic memory) and execu-
462 tive function [105]. Associated with lower activity
463 in these areas, AD patients have demonstrated poorer
464 encoding and retrieval than healthy individuals [106].
465 Simultaneously, increased activation in ventral lateral
466 prefrontal areas may be interpreted as a compensatory
467 mechanism in AD.

468 When considering the broader picture of cogni-
469 tive disturbances already detectable in early stages
470 of dementia, several other areas need to be men-
471 tioned. The thalamus, as a key area of the limbic
472 circuit and the episodic memory network, has also
473 been reported to be affected in early stage AD [107].
474 Alterations of the amygdala appear to have a pro-
475 found effect on emotional aspects of memory in AD
476 [108, 109]. Emotional stimuli, especially those with
477 negative valence, have altered influence on memory
478 functions in AD patients [110] and amygdala atrophy
479 has been correlated positively with emotional mem-
480 ory impairment severity [111]. Some recent studies
481 even pointed out other complex functions of the MTL,
482 including path integration, e.g., spatial representa-
483 tion, self-motion sensing, and temporal processing
484 [112]. Lesions of the anterior areas of the hippocam-
485 pus, parahippocampus, amygdala, and the anterior
486 and lateral section of temporal gyrus are associated
487 with poor performance on tests of delayed memory,
488 long-term memory and spatial memory. Addition-
489 ally, patients with alterations of these structures
490 have difficulties in target-directed walking because of
491 deficits of allocentric spatial information processing.

492 The picture is certainly much more complex and it
493 becomes increasingly difficult to decipher a causal
494 relationship. Nevertheless, the role of the hippocam-
495 pal region appears to be crucial in the occurrence and
496 progression of the cognitive impairment in MCI and
497 AD.

498 It is debated whether the extent of MTL structural
499 atrophy is a better predictor of clinical dementia as
500 compared to the memory deficit. Some studies found
501 that the ratio of amygdala volume loss and bilat-
502 eral entorhinal cortex shrinkage predicted time until
503 MCI symptom occurrence [113]. Others, for example
504 Visser et al., reported scores on cognitive test batter-
505 ies to serve as better predictors than MTL atrophy in
506 a longitudinal study design [114].

507 Considering that the volume of subcortical GM
508 critically impacts the size of neurons, glia cells, and
509 number of synapses it entails, we might hypothesize
510 that it affects the function and performance of these
511 structures. While deducing cognitive or any other
512 type of functional activity of subcortical GM solely
513 from their structural characteristics would be inad-
514 missibly simplified, observing changes in volume of
515 subcortical GM influenced by gender and aging might
516 yield better insight into several pathological condi-
517 tions, e.g., MCI and AD [115].

518 **TRANSITION FROM HEALTHY AGING** 519 **TO MILD COGNITIVE IMPAIRMENT** 520 **AND AD**

521 MCI is considered a precursor stage of AD with an
522 annual conversion rate of approximately 15% [116].
523 However, the clinical manifestation of MCI is still
524 not considered a predestination of a future conver-
525 sion to AD. One of the crucial biomarkers proposed
526 in the aim of a more valid diagnostic construct is
527 MTL atrophy [117]. A large number of studies have
528 focused on hippocampal volume loss focusing on
529 MCI conversion to AD reporting a non-uniform pat-
530 tern of hippocampal shrinkage. Converging research
531 evidence emphasizes the key role of the CA1 region
532 and subiculum showing the most significant involve-
533 ment throughout disease progression early on in the
534 course of illness [118–124]. While hippocampus vol-
535 ume has been reported to hold the highest predictive
536 accuracy for conversion to AD, the best multivariate
537 model for AD prediction, interestingly, consisted of
538 cognitive variables only [125].

539 A potential explanation for this seeming discrep-
540 ancly might be related to methods of imaging analysis

541 with more advanced techniques needed to ascertain
542 reliable and accurate data processing. The radial atro-
543 phy technique used to investigate subtle changes in
544 distinct regions of the hippocampus might be a useful
545 method in addressing prominent volume loss prior to
546 clinical pathology. Here, the CA1 region might be of
547 crucial importance, considering its robust volumet-
548 ric loss above the age of 60 also compared to other
549 regions of the hippocampus. However, if this is true
550 for the normal aging process, what could then be the
551 key turning point that eventually leads to the outcome
552 of dementia?

553 A view that gains increasing support offers an
554 explanation relying on neuroplasticity. Brain regions
555 characterized by high neuroplasticity have been
556 found to be especially vulnerable to neurodegener-
557 ation as well [126–128]. The CA1 region of the
558 hippocampus maintains its neuroplastic flexibility
559 well into adulthood presumably serving cognitive
560 capacity in interaction with external and internal
561 demands. Converging evidence supports the finding
562 that high level abilities of neuroplasticity are retained
563 late in life [129–131], especially in areas with long
564 axonal connections, such as the hippocampal region
565 [127]. The neurons in these regions might be able
566 to maintain their morphological and functional flex-
567 ibility to serve cognitive processes, however, these
568 abilities might on the other hand increase their vul-
569 nerability to neurotoxic effects eventually resulting
570 in structural and functional decline [132, 133]. The
571 hippocampal region is undoubtedly a key area for
572 high-order cognitive processes, such as memory and
573 learning, associated with high demands for neu-
574 roplasticity and neuronal flexibility [134, 135]. In
575 addition to this, other neuronal morphological pro-
576 cesses, such as dendritic spine plasticity, might also
577 play a crucial role in cognitive flexibility through-
578 out the lifespan [136]. This mechanism might be
579 involved in cognitive processes related to the CA1
580 region of the hippocampus [137, 138]. However,
581 this might also be a vulnerability component for
582 pathological effects, i.e., disturbed neurogenesis and
583 neuronal flexibility in the hippocampus has been
584 suggested as a crucial early component in cog-
585 nitive decline and even AD [139]. The relatively
586 rapid structural decline observed in postmenopausal
587 women in these vulnerable regions might further
588 accelerate the deterioration resulting in a vicious
589 circle [140]. This is supported by findings of
590 an age \times gender \times subcortical structural dependent
591 interaction with an impact on cognitive reserve abil-
592 ities [141].

RELEVANT MICROSTRUCTURAL AND PATHOBIOCHEMICAL CHANGES IN THE BACKGROUND OF STRUCTURAL AND FUNCTIONAL DETERIORATION

In the light of the presumably impaired neuroplasticity consequently leading to macrostructural changes in the hippocampal formation, one has to certainly address the microstructural neuropathology behind it. Focusing on specific hormonal effects, it has been shown that neuronal substrates associated with cognitive decline are significantly impacted by estrogens [142]. Research evidence indicates that most of estrogens' neuronal effects are related to brain derived estrogen, synthesized within the central nervous system [143, 144]. While levels of brain estrogen might largely differ from that of circulating estrogen, female brain estrogen levels have been found to relate well with blood estrogen levels measurable on the periphery [145]. Strikingly, a significant decline in brain-derived estrogen characterizes the postmenopausal period. It has also been suggested that this decline occurs mainly around menopause and, paired with a significant reduction in brain derived estrogen synthesis, it might lead to consequent cognitive deterioration [146, 147]. One key neuronal substrate that integrates several estrogen regulated molecular pathways is the mitochondria [148–150]. Estrogen receptors have been found in the mitochondria and the key role of mitochondria in estrogen associated neuroprotection has been supported by several different lines of evidence involving anti-inflammatory actions, anti-oxidant effects, and glutamate-related mechanisms among others (for an excellent review, see [151]). New evidence also indicates that a mitochondrial estrogen receptor deficiency found in the female AD brain results in impaired anti-inflammatory and anti-oxidative capacity of the mitochondria indicating vulnerability for neurodegeneration [152]. Our research has focused on the mitochondrial disturbances critical in aging, neurodegeneration, and AD specifically also involving the kynurenine system [153–155], glutamatergic mechanisms [156], and bioenergetic effects [157]. The complex interaction of these processes might well serve as a pathobiochemical and molecular background for the structural and functional alteration described in neurodegeneration. This is also supported by the relationship between worse pathological changes (i.e., amyloid depositions and total tau levels) and a more rapid hippocampal atrophy and cognitive decline in females, marking a potentially

increased vulnerability for the clinical manifestations of MCI and AD [158]. In the female brain, the menopausal period brings deterioration in the above mentioned bioenergetical balance with a potential lack of compensatory mechanisms representing a vulnerability to cognitive decline [159].

CONCLUDING REMARKS

AD is a growing healthcare issue worldwide demanding more and more precise characterization and identification of potential turning points from healthy aging to MCI and AD. An increasing body of research evidence has confirmed specific subcortical GM alterations in the brain during this process, evolving based on a hierarchical model. The firstly affected and most crucial areas are the components of MTL, especially the hippocampus. Endogenous and exogenous factors interacting with each other contribute to continuous alterations of these areas from our birth throughout adulthood. There are non-modifiable variables, such as age and gender, which have specific effects during aging, involving hormonal influence. In women, hippocampal volume loss appears to be accelerated in the postmenopausal period. This volume loss might be associated significantly and in a beginning stage with the neuroplasticity of the CA1 region in hippocampus, considering its high sensitivity to pathological alterations. The atrophy and consequent structural decline and functional impairment of this region evolving to other hippocampal and MTL areas might lead to the clinical manifestation of cognitive decline. This risk might be the greatest in the case of an already narrowed cognitive reserve capacity or subclinical cognitive impairment. Serving as a potential biomarker, specific structural hippocampal changes might be associated with consequent functional patterns of cognition, potentially supporting the identification of MCI and AD prior to the clinical symptoms of the disease. The interaction of age and gender combined with individual variables such brain-derived estrogen receptors, bioenergetical balance, and compensatory mechanisms should be taken altogether into consideration when assessing a potential occurrence of MCI and AD.

ACKNOWLEDGMENTS

The preparation of this review/opinion article was supported by the National Brain Research Program (Grant No. KTIA 13 NAP-A-III/9

and KTIA_13_NAP-A-II/20), the “Neuroscience Research Group of the Hungarian Academy of Sciences and University of Szeged”, the project FNUSA-ICRC (no. CZ.1.05/1.1.00/02.0123) from the European Regional Development Fund, by European Union - project ICRC-ERA-HumanBridge (No. 316345).

Authors’ disclosures available online (<http://j-alz.com/manuscript-disclosures/16-0812r1>).

REFERENCES

- [1] Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, Luchsinger JA, Ogunniyi A, Perry EK, Potocnik F, Prince M, Stewart R, Wimo A, Zhang ZX, Antuono P World Federation of Neurology Dementia Research G, (2008) Alzheimer’s disease and vascular dementia in developing countries: Prevalence, management, and risk factors. *Lancet Neurol* **7**, 812-826.
- [2] Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer’s disease. *Alzheimers Dement* **3**, 186-191.
- [3] Braak H, Braak E (1995) Staging of Alzheimer’s disease-related neurofibrillary changes. *Neurobiol Aging* **16**, 271-278; discussion 278-284.
- [4] Kincses ZT, Toldi J, Vecsei L (2010) Kynurenines, neurodegeneration and Alzheimer’s disease. *J Cell Mol Med* **14**, 2045-2054.
- [5] Yang J, Pan P, Song W, Huang R, Li J, Chen K, Gong Q, Zhong J, Shi H, Shang H (2012) Voxelwise meta-analysis of gray matter anomalies in Alzheimer’s disease and mild cognitive impairment using anatomic likelihood estimation. *J Neurol Sci* **316**, 21-29.
- [6] Herrup K (2010) Reimagining Alzheimer’s disease—an age-based hypothesis. *J Neurosci* **30**, 16755-16762.
- [7] Fiest KM, Jette N, Roberts JI, Maxwell CJ, Smith EE, Black SE, Blaikie L, Cohen A, Day L, Holroyd-Leduc J, Kirk A, Pearson D, Pringsheim T, Venegas-Torres A, Hogan DB (2016) The prevalence and incidence of dementia: A systematic review and meta-analysis. *Can J Neurol Sci* **43**(Suppl 1), S3-S50.
- [8] Fiest KM, Roberts JI, Maxwell CJ, Hogan DB, Smith EE, Frolkis A, Cohen A, Kirk A, Pearson D, Pringsheim T, Venegas-Torres A, Jette N (2016) The prevalence and incidence of dementia due to Alzheimer’s disease: A systematic review and meta-analysis. *Can J Neurol Sci* **43**(Suppl 1), S51-S82.
- [9] Carter CL, Resnick EM, Mallampalli M, Kalbarczyk A (2012) Sex and gender differences in Alzheimer’s disease: Recommendations for future research. *J Womens Health (Larchmt)* **21**, 1018-1023.
- [10] Gao S, Hendrie HC, Hall KS, Hui S (1998) The relationships between age, sex, and the incidence of dementia and Alzheimer disease: A meta-analysis. *Arch Gen Psychiatry* **55**, 809-815.
- [11] Hebert LE, Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. *Neurology* **80**, 1778-1783.
- [12] Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MM (2001) Incidence of dementia: Does gender make a difference? *Neurobiol Aging* **22**, 575-580.
- [13] Stepan-Buksakowska I, Szabo N, Horinek D, Toth E, Hort J, Warner J, Charvat F, Vecsei L, Roczek M, Kincses ZT (2014) Cortical and subcortical atrophy in Alzheimer disease: Parallel atrophy of thalamus and hippocampus. *Alzheimer Dis Assoc Disord* **28**, 65-72.
- [14] Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BT, Albert MS (2000) Use of structural magnetic resonance imaging to predict who will get Alzheimer’s disease. *Ann Neurol* **47**, 430-439.
- [15] Ferreira LK, Diniz BS, Forlenza OV, Busatto GF, Zanetti MV (2011) Neurostructural predictors of Alzheimer’s disease: A meta-analysis of VBM studies. *Neurobiol Aging* **32**, 1733-1741.
- [16] Kincses ZT, Horinek D, Szabo N, Toth E, Csete G, Stepan-Buksakowska I, Hort J, Vecsei L (2013) The pattern of diffusion parameter changes in Alzheimer’s disease, identified by means of linked independent component analysis. *J Alzheimers Dis* **36**, 119-128.
- [17] Chetelat G, Baron JC (2003) Early diagnosis of Alzheimer’s disease: Contribution of structural neuroimaging. *Neuroimage* **18**, 525-541.
- [18] Liu Y, Wang K, Yu C, He Y, Zhou Y, Liang M, Wang L, Jiang T (2008) Regional homogeneity, functional connectivity and imaging markers of Alzheimer’s disease: A review of resting-state fMRI studies. *Neuropsychologia* **46**, 1648-1656.
- [19] Dai Z, He Y (2014) Disrupted structural and functional brain connectomes in mild cognitive impairment and Alzheimer’s disease. *Neurosci Bull* **30**, 217-232.
- [20] Shi F, Liu B, Zhou Y, Yu C, Jiang T (2009) Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer’s disease: Meta-analyses of MRI studies. *Hippocampus* **19**, 1055-1064.
- [21] Risacher SL, Saykin AJ (2013) Neuroimaging and other biomarkers for Alzheimer’s disease: The changing landscape of early detection. *Annu Rev Clin Psychol* **9**, 621-648.
- [22] Courchesne E, Chisum HJ, Townsend J, Cowles A, Covington J, Egaas B, Harwood M, Hinds S, Press GA (2000) Normal brain development and aging: Quantitative analysis of in vivo MR imaging in healthy volunteers. *Radiology* **216**, 672-682.
- [23] Gur RC, Mozley PD, Resnick SM, Gottlieb GL, Kohn M, Zimmerman R, Herman G, Atlas S, Grossman R, Berretta D et al. (1991) Gender differences in age effect on brain atrophy measured by magnetic resonance imaging. *Proc Natl Acad Sci U S A* **88**, 2845-2849.
- [24] Scahill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC (2003) A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. *Arch Neurol* **60**, 989-994.
- [25] Ge Y, Grossman RI, Babb JS, Rabin ML, Mannon LJ, Kolson DL (2002) Age-related total gray matter and white matter changes in normal adult brain. Part I: Volumetric MR imaging analysis. *AJNR Am J Neuroradiol* **23**, 1327-1333.
- [26] Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS (2001) A voxel-based morphometric study of ageing in 465 normal adult human brains. *Neuroimage* **14**, 21-36.
- [27] Guttman CR, Jolesz FA, Kikinis R, Killiany RJ, Moss MB, Sandor T, Albert MS (1998) White matter changes with normal aging. *Neurology* **50**, 972-978.
- [28] Pell GS, Briellmann RS, Chan CH, Pardoe H, Abbott DF, Jackson GD (2008) Selection of the control group

- 814 for VBM analysis: Influence of covariates, matching and
815 sample size. *Neuroimage* **41**, 1324-1335.
- 816 [29] Smith CD, Chebrolu H, Wekstein DR, Schmitt FA,
817 Markesbery WR (2007) Age and gender effects on human
818 brain anatomy: A voxel-based morphometric study in
819 healthy elderly. *Neurobiol Aging* **28**, 1075-1087.
- 820 [30] Sowell ER, Peterson BS, Kan E, Woods RP, Yoshii J,
821 Bansal R, Xu D, Zhu H, Thompson PM, Toga AW
822 (2007) Sex differences in cortical thickness mapped in 176
823 healthy individuals between 7 and 87 years of age. *Cereb*
824 *Cortex* **17**, 1550-1560.
- 825 [31] Allen JS, Bruss J, Brown CK, Damasio H (2005) Normal
826 neuroanatomical variation due to age: The major lobes and
827 a parcellation of the temporal region. *Neurobiol Aging* **26**,
828 1245-1260; discussion 1279-1282.
- 829 [32] Raz N, Rodrigue KM (2006) Differential aging of the
830 brain: Patterns, cognitive correlates and modifiers. *Neurosci*
831 *Biobehav Rev* **30**, 730-748.
- 832 [33] Taki Y, Goto R, Evans A, Zijdenbos A, Neelin P, Lerch
833 J, Sato K, Ono S, Kinomura S, Nakagawa M, Sugiura M,
834 Watanabe J, Kawashima R, Fukuda H (2004) Voxel-based
835 morphometry of human brain with age and cerebrovascular
836 risk factors. *Neurobiol Aging* **25**, 455-463.
- 837 [34] Fjell AM, Westlye LT, Grydeland H, Amlien I, Espeseth
838 T, Reinvang I, Raz N, Holland D, Dale AM, Walhovd KB,
839 Alzheimer Disease Neuroimaging Initiative (2013) Critical
840 ages in the life course of the adult brain: Nonlinear
841 subcortical aging. *Neurobiol Aging* **34**, 2239-2247.
- 842 [35] Curiati PK, Tamashiro JH, Squarozzi P, Duran FL, Santos
843 LC, Wajngarten M, Leite CC, Vallada H, Menezes PR,
844 Sczufca M, Busatto GF, Alves TC (2009) Brain structural
845 variability due to aging and gender in cognitively healthy
846 Elders: Results from the Sao Paulo Ageing and Health
847 study. *AJNR Am J Neuroradiol* **30**, 1850-1856.
- 848 [36] Ostby Y, Tamnes CK, Fjell AM, Westlye LT, Due-
849 Tonnessen P, Walhovd KB (2009) Heterogeneity in
850 subcortical brain development: A structural magnetic resonance
851 imaging study of brain maturation from 8 to 30
852 years. *J Neurosci* **29**, 11772-11782.
- 853 [37] Fjell AM, Walhovd KB, Westlye LT, Ostby Y, Tamnes
854 CK, Jernigan TL, Gamst A, Dale AM (2010) When does
855 brain aging accelerate? Dangers of quadratic fits in cross-
856 sectional studies. *Neuroimage* **50**, 1376-1383.
- 857 [38] Fjell AM, Walhovd KB (2010) Structural brain changes in
858 aging: Courses, causes and cognitive consequences. *Rev*
859 *Neurosci* **21**, 187-221.
- 860 [39] Jernigan TL, Gamst AC (2005) Changes in volume with
861 age-consistency and interpretation of observed effects.
862 *Neurobiol Aging* **26**, 1271-1274; discussion 1275-1278.
- 863 [40] Raz N, Lindenberger U (2011) Only time will tell:
864 Cross-sectional studies offer no solution to the age-brain-
865 cognition triangle: Comment on Salthouse (2011). *Psychol*
866 *Bull* **137**, 790-795.
- 867 [41] Fjell AM, Sneve MH, Storsve AB, Grydeland H, Yendiki
868 A, Walhovd KB (2016) Brain events underlying episodic
869 memory changes in aging: A longitudinal investigation of
870 structural and functional connectivity. *Cereb Cortex* **26**,
871 1272-1286.
- 872 [42] Ahsan RL, Allom R, Gousias IS, Habib H, Turkheimer
873 FE, Free S, Lemieux L, Myers R, Duncan JS, Brooks DJ,
874 Koepp MJ, Hammers A (2007) Volumes, spatial extents
875 and a probabilistic atlas of the human basal ganglia and
876 thalamus. *Neuroimage* **38**, 261-270.
- 877 [43] Raz N, Gunning FM, Head D, Dupuis JH, McQuain J,
878 Briggs SD, Loken WJ, Thornton AE, Acker JD (1997)
879 Selective aging of the human cerebral cortex observed
880 in vivo: Differential vulnerability of the prefrontal gray
881 matter. *Cereb Cortex* **7**, 268-282.
- 882 [44] Ge Y, Grossman RI, Babb JS, Rabin ML, Mannon LJ,
883 Kolson DL (2002) Age-related total gray matter and white
884 matter changes in normal adult brain. Part II: Quantitative
885 magnetization transfer ratio histogram analysis. *AJNR Am*
886 *J Neuroradiol* **23**, 1334-1341.
- 887 [45] Skup M, Zhu H, Wang Y, Giovanello KS, Lin JA, Shen D,
888 Shi F, Gao W, Lin W, Fan Y, Zhang H, Alzheimer's Disease
889 Neuroimaging Initiative (2011) Sex differences in grey
890 matter atrophy patterns among AD and aMCI patients:
891 Results from ADNI. *Neuroimage* **56**, 890-906.
- 892 [46] Katzman R, Terry R, DeTeresa R, Brown T, Davies P,
893 Fuld P, Renbing X, Peck A (1988) Clinical, pathological,
894 and neurochemical changes in dementia: A subgroup with
895 preserved mental status and numerous neocortical plaques.
896 *Ann Neurol* **23**, 138-144.
- 897 [47] Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans
898 DA, Bennett DA (2005) Sex differences in the clinical
899 manifestations of Alzheimer disease pathology. *Arch Gen*
900 *Psychiatry* **62**, 685-691.
- 901 [48] Taber KH, Murphy DD, Blurton-Jones MM, Hurley RA
902 (2001) An update on estrogen: Higher cognitive function,
903 receptor mapping, neurotrophic effects. *J Neuropsychiatry*
904 *Clin Neurosci* **13**, 313-317.
- 905 [49] Luders E, Gaser C, Narr KL, Toga AW (2009) Why sex
906 matters: Brain size independent differences in gray matter
907 distributions between men and women. *J Neurosci* **29**,
908 14265-14270.
- 909 [50] Murphy DG, DeCarli C, McIntosh AR, Daly E, Mentis
910 MJ, Pietrini P, Szczepanik J, Schapiro MB, Grady CL,
911 Horwitz B, Rapoport SI (1996) Sex differences in human
912 brain morphometry and metabolism: An in vivo quantitative
913 magnetic resonance imaging and positron emission
914 tomography study on the effect of aging. *Arch Gen Psy-*
915 *chiatry* **53**, 585-594.
- 916 [51] Takahashi R, Ishii K, Kakigi T, Yokoyama K (2011) Gender
917 and age differences in normal adult human brain:
918 Voxel-based morphometric study. *Hum Brain Mapp* **32**,
919 1050-1058.
- 920 [52] Sullivan EV, Rosenbloom M, Serventi KL, Pfefferbaum A
921 (2004) Effects of age and sex on volumes of the thalamus,
922 pons, and cortex. *Neurobiol Aging* **25**, 185-192.
- 923 [53] Rijpkema M, Everaerd D, van der Pol C, Franke B, Tendol-
924 kar I, Fernandez G (2012) Normal sexual dimorphism
925 in the human basal ganglia. *Hum Brain Mapp* **33**, 1246-
926 1252.
- 927 [54] Cheng Y, Chou KH, Decety J, Chen IY, Hung D, Tzeng
928 OJ, Lin CP (2009) Sex differences in the neuroanatomy of
929 human mirror-neuron system: A voxel-based morphometric
930 investigation. *Neuroscience* **158**, 713-720.
- 931 [55] Lemaitre H, Crivello F, Grassiot B, Alperovitch A, Tzourio
932 C, Mazoyer B (2005) Age- and sex-related effects on
933 the neuroanatomy of healthy elderly. *Neuroimage* **26**,
934 900-911.
- 935 [56] Kiraly A, Szabo N, Toth E, Csete G, Farago P, Kocsis K,
936 Must A, Vecsei L, Kincses ZT (2016) Male brain ages
937 faster: The age and gender dependence of subcortical volumes.
938 *Brain Imaging Behav* **10**, 901-910.
- 939 [57] Perlaki G, Orsi G, Plozer E, Altbacker A, Darnai G, Nagy
940 SA, Horvath R, Toth A, Doczi T, Kovacs N, Bogner
941 P, Schwarcz A, Janszky J (2014) Are there any gender
942 differences in the hippocampus volume after head-size
943 correction? A volumetric and voxel-based morphometric
944 study. *Neurosci Lett* **570**, 119-123.

- 945 [58] Li W, van Tol MJ, Li M, Miao W, Jiao Y, Heinze HJ, Bogerts B, He H, Walter M (2014) Regional specificity of sex effects on subcortical volumes across the lifespan in healthy aging. *Hum Brain Mapp* **35**, 238-247. 1010
- 946 1011
- 947 1012
- 948 1013
- 949 [59] Herrero MT, Barcia C, Navarro JM (2002) Functional anatomy of thalamus and basal ganglia. *Childs Nerv Syst* **18**, 386-404. 1014
- 950 1015
- 951 1016
- 952 [60] Xu J, Kobayashi S, Yamaguchi S, Iijima K, Okada K, Yamashita K (2000) Gender effects on age-related changes in brain structure. *AJNR Am J Neuroradiol* **21**, 112-118. 1017
- 953 1018
- 954 [61] Clark CR, Paul RH, Williams LM, Arns M, Fallahpour K, Handmer C, Gordon E (2006) Standardized assessment of synaptic plasticity by brain estrogen in the hippocampus. *Biochim Biophys Acta* **1800**, 1030-1044. 1019
- 955 1020
- 956 [62] Finkel D, Reynolds CA, Berg S, Pedersen NL (2006) Surprising lack of sex differences in normal cognitive aging in twins. *Int J Aging Hum Dev* **62**, 335-357. 1021
- 957 1022
- 958 [63] Kave G, Shrira A, Palgi Y, Spalter T, Ben-Ezra M, Shmotkin D (2012) Formal education level versus self-rated literacy as predictors of cognitive aging. *J Gerontol B Psychol Sci Soc Sci* **67**, 697-704. 1023
- 959 1024
- 960 [64] Barron AM, Pike CJ (2012) Sex hormones, aging, and androgen. *J Steroid Biochem Mol Biol* **131**, 37-51. 1025
- 961 1026
- 962 [65] Neufang S, Specht K, Hausmann M, Gunturkun O, Herpertz-Dahlmann B, Fink GR, Konrad K (2009) Sex differences and the impact of steroid hormones on the developing human brain. *Cereb Cortex* **19**, 464-473. 1027
- 963 1028
- 964 [66] Kesler SR, Garrett A, Bender B, Yankowitz J, Zeng SM, Reiss AL (2004) Amygdala and hippocampal volumes in Turner syndrome: A high-resolution MRI study of X-monosomy. *Neuropsychologia* **42**, 1971-1978. 1029
- 965 1030
- 966 [67] Shughrue PJ, Lane MV, Merchenthaler I (1997) Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. *J Comp Neurol* **388**, 507-525. 1031
- 967 1032
- 968 [68] Kesler SR, Haberecht MF, Menon V, Warsofsky IS, Dyer-Friedman J, Neely EK, Reiss AL (2004) Sex hormones, aging, and Alzheimer's disease. *Front Biosci (Elite Ed)* **4**, 976-997. 1033
- 969 1034
- 970 [69] Azad NA, Al Bugami M, Loy-English I (2007) Gender differences and the impact of steroid hormones on the developing human brain. *Cereb Cortex* **19**, 464-473. 1035
- 971 1036
- 972 [70] Vina J, Lloret A (2010) Why women have more cognitive impairment than men: Gender and mitochondrial toxicity of amyloid-beta peptide. *J Alzheimers Dis* **20**(Suppl 2), S527-S533. 1037
- 973 1038
- 974 [71] Dye RV, Miller KJ, Singer EJ, Levine AJ (2012) Hormone replacement therapy and risk for neurodegenerative diseases. *Int J Alzheimers Dis* **2012**, 258454. 1039
- 975 1040
- 976 [72] Hogervorst E (2013) Sex hormones and mental rotation: An intensive longitudinal investigation. *Horm Behav* **63**, 345-351. 1041
- 977 1042
- 978 [73] McClure RE, Barha CK, Galea LA (2013) 17beta-Estradiol, but not estrone, increases the survival and cognitive function of new neurons in the hippocampus in response to spatial memory in adult female rats. *Horm Behav* **63**, 144-157. 1043
- 979 1044
- 980 [74] Galea LA, Wainwright SR, Roes MM, Duarte-Guterman P, Chow C, Hamson DK (2013) Sex, hormones and neurogenesis in the hippocampus: Hormonal modulation of neurogenesis and potential functional implications. *J Neuroendocrinol* **25**, 1039-1061. 1045
- 981 1046
- 982 [75] Hojo Y, Hattori TA, Enami T, Furukawa A, Suzuki K, Ishii HT, Mukai H, Morrison JH, Janssen WG, Kominami S, Harada N, Kimoto T, Kawato S (2004) Adult male rat hippocampus synthesizes estradiol from pregnenolone by cytochromes P45017alpha and P450 aromatase localized in neurons. *Proc Natl Acad Sci U S A* **101**, 865-870. 1047
- 983 1048
- 984 1049
- 985 1050
- 986 1051
- 987 1052
- 988 1053
- 989 1054
- 990 1055
- 991 1056
- 992 1057
- 993 1058
- 994 1059
- 995 1060
- 996 1061
- 997 1062
- 998 1063
- 999 1064
- 1000 1065
- 1001 1066
- 1002 1067
- 1003 1068
- 1004 1069
- 1005 1070
- 1006 1071
- 1007 1072
- 1008 1073
- 1009 1074
- [76] von Schassen C, Fester L, Prange-Kiel J, Lohse C, Huber C, Bottner M, Rune GM (2006) Oestrogen synthesis in the hippocampus: Role in axon outgrowth. *J Neuroendocrinol* **18**, 847-856. 1010
- [77] Mukai H, Kimoto T, Hojo Y, Kawato S, Murakami G, Higo S, Hatanaka Y, Ogiue-Ikeda M (2010) Modulation of synaptic plasticity by brain estrogen in the hippocampus. *Biochim Biophys Acta* **1800**, 1030-1044. 1011
- [78] Ooishi Y, Kawato S, Hojo Y, Hatanaka Y, Higo S, Murakami G, Komatsuzaki Y, Ogiue-Ikeda M, Kimoto T, Mukai H (2012) Modulation of synaptic plasticity in the hippocampus by hippocampus-derived estrogen and androgen. *J Steroid Biochem Mol Biol* **131**, 37-51. 1012
- [79] Spencer-Segal JL, Tsuda MC, Mattei L, Waters EM, Romeo RD, Milner TA, McEwen BS, Ogawa S (2012) Estradiol acts via estrogen receptors alpha and beta on pathways important for synaptic plasticity in the mouse hippocampal formation. *Neuroscience* **202**, 131-146. 1013
- [80] Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ, Alzheimer's Disease Cooperative Study Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. *Arch Neurol* **62**, 953-957. 1014
- [81] Courvoisier DS, Renaud O, Geiser C, Paschke K, Gaudy K, Jordan K (2013) Sex hormones and mental rotation: An intensive longitudinal investigation. *Horm Behav* **63**, 345-351. 1015
- [82] Erickson KI, Voss MW, Prakash RS, Chaddock L, Kramer AF (2010) A cross-sectional study of hormone treatment and hippocampal volume in postmenopausal women: Evidence for a limited window of opportunity. *Neuropsychology* **24**, 68-76. 1016
- [83] Goto M, Abe O, Miyati T, Inano S, Hayashi N, Aoki S, Mori H, Kabasawa H, Ino K, Yano K, Iida K, Mima K, Ohtomo K (2011) 3 Tesla MRI detects accelerated hippocampal volume reduction in postmenopausal women. *J Magn Reson Imaging* **33**, 48-53. 1017
- [84] Guenzel FM, Wolf OT, Schwabe L (2014) Sex differences in stress effects on response and spatial memory formation. *Neurobiol Learn Mem* **109**, 46-55. 1018
- [85] Galea LA, Leuner B, Slattery DA (2014) Hippocampal plasticity during the peripartum period: Influence of sex steroids, stress and ageing. *J Neuroendocrinol* **26**, 641-648. 1019
- [86] Jung RE, Ryman SG, Vakhtin AA, Carrasco J, Wertz C, Flores RA (2014) Subcortical correlates of individual differences in aptitude. *PLoS One* **9**, e89425. 1020
- [87] Li R, Cui J, Shen Y (2014) Brain sex matters: Estrogen in cognition and Alzheimer's disease. *Mol Cell Endocrinol* **389**, 13-21. 1021
- [88] Waber DP (1979) Neuropsychological aspects of Turner's syndrome. *Dev Med Child Neurol* **21**, 58-70. 1022
- [89] Ryan J, Carriere I, Scali J, Ritchie K, Ancelin ML (2009) Life-time estrogen exposure and cognitive functioning in later life. *Psychoneuroendocrinology* **34**, 287-298. 1023
- [90] Sherwin BB, Henry JF (2008) Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: A critical review. *Front Neuroendocrinol* **29**, 88-113. 1024

- 1075 [91] de Frias CM, Nilsson LG, Herlitz A (2006) Sex differ- 1140
 1076 ences in cognition are stable over a 10-year period in 1141
 1077 adulthood and old age. *Neuropsychol Dev Cogn B Aging* 1142
 1078 *Neuropsychol Cogn* **13**, 574-587. 1143
- 1079 [92] Wiederholt WC, Cahn D, Butters NM, Salmon DP, Kritz- 1144
 1080 Silverstein D, Barrett-Connor E (1993) Effects of age, 1145
 1081 gender and education on selected neuropsychological tests 1146
 1082 in an elderly community cohort. *J Am Geriatr Soc* **41**, 1147
 1083 639-647. 1148
- 1084 [93] Laws KR, Duncan A, Gale TM (2010) 'Normal' semantic- 1149
 1085 phonemic fluency discrepancy in Alzheimer's disease? A 1150
 1086 meta-analytic study. *Cortex* **46**, 595-601. 1151
- 1087 [94] van Hooren SA, Valentijn AM, Bosma H, Ponds RW, 1152
 1088 van Boxtel MP, Jolles J (2007) Cognitive functioning in 1153
 1089 healthy older adults aged 64-81: A cohort study into the 1154
 1090 effects of age, sex, and education. *Neuropsychol Dev Cogn* 1155
 1091 *B Aging Neuropsychol Cogn* **14**, 40-54. 1156
- 1092 [95] Irvine K, Laws KR, Gale TM, Kondel TK (2012) 1157
 1093 Greater cognitive deterioration in women than men with 1158
 1094 Alzheimer's disease: A meta analysis. *J Clin Exp Neu-* 1159
 1095 *ropsychol* **34**, 989-998. 1160
- 1096 [96] Dekhtyar S, Wang HX, Fratiglioni L, Herlitz A (2016) 1161
 1097 Childhood school performance, education and occupa- 1162
 1098 tional complexity: A life-course study of dementia in 1163
 1099 the Kungsholmen Project. *Int J Epidemiol*, doi: 1164
 1100 10.1093/ije/dyw008 1165
- 1101 [97] Johansson L, Guo X, Waern M, Ostling S, Gustafson D, 1166
 1102 Bengtsson C, Skoog I (2010) Midlife psychological stress 1167
 1103 and risk of dementia: A 35-year longitudinal population 1168
 1104 study. *Brain* **133**, 2217-2224. 1169
- 1105 [98] Comijs HC, van den Kommer TN, Minnaar RW, Pen- 1170
 1106 ninx BW, Deeg DJ (2011) Accumulated and differential 1171
 1107 effects of life events on cognitive decline in older persons: 1172
 1108 Depending on depression, baseline cognition, or ApoE 1173
 1109 epsilon4 status? *J Gerontol B Psychol Sci Soc Sci* **66**(Suppl 1174
 1110 1), i111-i120. 1175
- 1111 [99] Hodges JR, Patterson K (1995) Is semantic memory con- 1176
 1112 sistentlly impaired early in the course of Alzheimer's 1177
 1113 disease? Neuroanatomical and diagnostic implications. 1178
 1114 *Neuropsychologia* **33**, 441-459. 1179
- 1115 [100] Sheardova K, Laczko J, Vyhalek M, Andel R, Mokrisova 1180
 1116 I, Vlcek K, Amlerova J, Hort J (2014) Famous landmark 1181
 1117 identification in amnesic mild cognitive impairment and 1182
 1118 Alzheimer's disease. *PLoS One* **9**, e105623. 1183
- 1119 [101] Ryan L, Lin CY, Ketcham K, Nadel L (2010) The role of 1184
 1120 medial temporal lobe in retrieving spatial and nonspatial 1185
 1121 relations from episodic and semantic memory. *Hippocam-* 1186
 1122 *pus* **20**, 11-18. 1187
- 1123 [102] Cummings JL (2000) Cognitive and behavioral hetero- 1188
 1124 geneity in Alzheimer's disease: Seeking the neurobiolog- 1189
 1125 ical basis. *Neurobiol Aging* **21**, 845-861. 1190
- 1126 [103] Elgh E, Lindqvist Astot A, Fagerlund M, Eriksson S, 1191
 1127 Olsson T, Nasman B (2006) Cognitive dysfunction, 1192
 1128 hippocampal atrophy and glucocorticoid feedback in 1193
 1129 Alzheimer's disease. *Biol Psychiatry* **59**, 155-161. 1194
- 1130 [104] Velayudhan L, Proitsi P, Westman E, Muehlboeck JS, 1195
 1131 Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, 1196
 1132 Spenger C, Hodges A, Powell J, Lovestone S, Simmons A, 1197
 1133 dNeuroMed Consortium (2013) Entorhinal cortex thick- 1198
 1134 ness predicts cognitive decline in Alzheimer's disease. *J* 1199
 1135 *Alzheimers Dis* **33**, 755-766. 1200
- 1136 [105] Nho K, Risacher SL, Crane PK, DeCarli C, Glymour MM, 1201
 1137 Habeck C, Kim S, Lee GJ, Mormino E, Mukherjee S, Shen 1202
 1138 L, West JD, Saykin AJ, Alzheimer's Disease Neuroimaging 1203
 1139 Initiative (2012) Voxel and surface-based topography 1204
- of memory and executive deficits in mild cognitive impair- 1140
 ment and Alzheimer's disease. *Brain Imaging Behav* **6**, 1141
 551-567. 1142
- [106] Schwindt GC, Black SE (2009) Functional imaging 1143
 studies of episodic memory in Alzheimer's disease: A 1144
 quantitative meta-analysis. *Neuroimage* **45**, 181-190. 1145
- [107] Aggleton JP, Pralus A, Nelson AJ, Hornberger M (2016) 1146
 Thalamic pathology and memory loss in early Alzheimer's 1147
 disease: Moving the focus from the medial temporal lobe 1148
 to Papez circuit. *Brain* **139**, 1877-1890. 1149
- [108] Brierley B, Medford N, Shaw P, David AS (2004) Emo- 1150
 tional memory and perception in temporal lobectomy 1151
 patients with amygdala damage. *J Neurol Neurosurg Psy-* 1152
chiatry **75**, 593-599. 1153
- [109] Richter-Levin G (2004) The amygdala, the hippocampus, 1154
 and emotional modulation of memory. *Neuroscientist* **10**, 1155
 31-39. 1156
- [110] Sundstrom M (2011) Modeling recall memory for emo- 1157
 tional objects in Alzheimer's disease. *Neuropsychol Dev* 1158
Cogn B Aging Neuropsychol Cogn **18**, 396-413. 1159
- [111] Fleming K, Kim SH, Doo M, Maguire G, Potkin SG 1160
 (2003) Memory for emotional stimuli in patients with 1161
 Alzheimer's disease. *Am J Alzheimers Dis Other Demen* 1162
18, 340-342. 1163
- [112] Yamamoto N, Philbeck JW, Woods AJ, Gajewski DA, 1164
 Arthur JC, Potolicchio SJ Jr, Levy L, Caputy AJ (2014) 1165
 Medial temporal lobe roles in human path integration. 1166
PLoS One **9**, e96583. 1167
- [113] Soldan A, Pettigrew C, Lu Y, Wang MC, Selnes O, Albert 1168
 M, Brown T, Ratnanather JT, Younes L, Miller MI, Team 1169
 BR (2015) Relationship of medial temporal lobe atrophy, 1170
 APOE genotype, and cognitive reserve in preclinical 1171
 Alzheimer's disease. *Hum Brain Mapp* **36**, 2826-2841. 1172
- [114] Visser PJ, Scheltens P, Verhey FR, Schmand B, Launer LJ, 1173
 Jolles J, Jonker C (1999) Medial temporal lobe atrophy and 1174
 memory dysfunction as predictors for dementia in subjects 1175
 with mild cognitive impairment. *J Neurol* **246**, 477-485. 1176
- [115] Qian S, Zhang Z, Li B, Sun G (2015) Functional-structural 1177
 degeneration in dorsal and ventral attention systems for 1178
 Alzheimer's disease, amnesic mild cognitive impairment. 1179
Brain Imaging Behav **9**, 790-800. 1180
- [116] Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, 1181
 Rabins PV, Ritchie K, Rosser M, Thal L, Winblad B 1182
 (2001) Current concepts in mild cognitive impairment. 1183
Arch Neurol **58**, 1985-1992. 1184
- [117] Dubois B, Feldman HH, Jacova C, Dekosky ST, 1185
 Barberger-Gateau P, Cummings J, Delacourte A, Galasko 1186
 D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier 1187
 F, Robert P, Rosser M, Salloway S, Stern Y, Visser PJ, 1188
 Scheltens P (2007) Research criteria for the diagnosis of 1189
 Alzheimer's disease: Revising the NINCDS-ADRDA 1190
 criteria. *Lancet Neurol* **6**, 734-746. 1191
- [118] Rossler M, Zarski R, Bohl J, Ohm TG (2002) 1192
 Stage-dependent and sector-specific neuronal loss in hip- 1193
 pocampus during Alzheimer's disease. *Acta Neuropathol* 1194
103, 363-369. 1195
- [119] West MJ, Kawas CH, Stewart WF, Rudow GL, Tron- 1196
 coso JC (2004) Hippocampal neurons in pre-clinical 1197
 Alzheimer's disease. *Neurobiol Aging* **25**, 1205-1212. 1198
- [120] Apostolova LG, Dinov ID, Dutton RA, Hayashi KM, Toga 1199
 AW, Cummings JL, Thompson PM (2006) 3D comparison 1200
 of hippocampal atrophy in amnesic mild cognitive impair- 1201
 ment and Alzheimer's disease. *Brain* **129**, 2867-2873. 1202
- [121] Apostolova LG, Dutton RA, Dinov ID, Hayashi KM, Toga 1203
 AW, Cummings JL, Thompson PM (2006) Conversion 1204

- of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. *Arch Neurol* **63**, 693-699.
- [122] Apostolova LG, Mosconi L, Thompson PM, Green AE, Hwang KS, Ramirez A, Mistur R, Tsui WH, de Leon MJ (2010) Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. *Neurobiol Aging* **31**, 1077-1088.
- [123] Apostolova LG, Thompson PM, Green AE, Hwang KS, Zoumalan C, Jack CR Jr, Harvey DJ, Petersen RC, Thal LJ, Aisen PS, Toga AW, Cummings JL, Decarli CS (2010) 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. *Hum Brain Mapp* **31**, 786-797.
- [124] West MJ, Coleman PD, Flood DG, Troncoso JC (1994) Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. *Lancet* **344**, 769-772.
- [125] Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR Jr, Aisen PS, Thal LJ (2008) Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. *Neurology* **70**, 191-199.
- [126] Bufill E, Blesa R, Augusti J (2013) Alzheimer's disease: An evolutionary approach. *J Anthropol Sci* **91**, 135-157.
- [127] Rapoport SI, Nelson PT (2011) Biomarkers and evolution in Alzheimer disease. *Prog Neurobiol* **95**, 510-513.
- [128] Neill D (2012) Should Alzheimer's disease be equated with human brain ageing? A maladaptive interaction between brain evolution and senescence. *Ageing Res Rev* **11**, 104-122.
- [129] Boyke J, Driemeyer J, Gaser C, Buchel C, May A (2008) Training-induced brain structure changes in the elderly. *J Neurosci* **28**, 7031-7035.
- [130] Engvig A, Fjell AM, Westlye LT, Skaane NV, Sundseth O, Walhovd KB (2012) Hippocampal subfield volumes correlate with memory training benefit in subjective memory impairment. *Neuroimage* **61**, 188-194.
- [131] Engvig A, Fjell AM, Westlye LT, Moberget T, Sundseth O, Larsen VA, Walhovd KB (2012) Memory training impacts short-term changes in aging white matter: A longitudinal diffusion tensor imaging study. *Hum Brain Mapp* **33**, 2390-2406.
- [132] Walhovd KB, Fjell AM, Espeseth T (2014) Cognitive decline and brain pathology in aging—need for a dimensional, lifespan and systems vulnerability view. *Scand J Psychol* **55**, 244-254.
- [133] Walhovd KB, Tamnes CK, Fjell AM (2014) Brain structural maturation and the foundations of cognitive behavioral development. *Curr Opin Neurol* **27**, 176-184.
- [134] Aimone JB, Deng W, Gage FH (2010) Adult neurogenesis: Integrating theories and separating functions. *Trends Cogn Sci* **14**, 325-337.
- [135] Deng W, Aimone JB, Gage FH (2010) New neurons and new memories: How does adult hippocampal neurogenesis affect learning and memory? *Nat Rev Neurosci* **11**, 339-350.
- [136] Benavides-Piccione R, Fernaud-Espinosa I, Robles V, Yuste R, DeFelipe J (2013) Age-based comparison of human dendritic spine structure using complete three-dimensional reconstructions. *Cereb Cortex* **23**, 1798-1810.
- [137] Sanders J, Cowansage K, Baumgartel K, Mayford M (2012) Elimination of dendritic spines with long-term memory is specific to active circuits. *J Neurosci* **32**, 12570-12578.
- [138] Attardo A, Fitzgerald JE, Schnitzer MJ (2015) Impermanence of dendritic spines in live adult CA1 hippocampus. *Nature* **523**, 592-596.
- [139] Mu Y, Gage FH (2011) Adult hippocampal neurogenesis and its role in Alzheimer's disease. *Mol Neurodegener* **6**, 85.
- [140] Vierk R, Bayer J, Freitag S, Muhia M, Kutsche K, Wolbers T, Kneussel M, Sommer T, Rune GM (2015) Structure-function-behavior relationship in estrogen-induced synaptic plasticity. *Horm Behav* **74**, 139-148.
- [141] Pernecky R, Drzezga A, Diehl-Schmid J, Li Y, Kurz A (2007) Gender differences in brain reserve: An (18)F-FDG PET study in Alzheimer's disease. *J Neurol* **254**, 1395-1400.
- [142] Prokai L, Simpkins JW (2007) Structure-nongenomic neuroprotection relationship of estrogens and estrogen-derived compounds. *Pharmacol Ther* **114**, 1-12.
- [143] Fester L, Rune GM (2015) Sexual neurosteroids and synaptic plasticity in the hippocampus. *Brain Res* **1621**, 162-169.
- [144] Arevalo MA, Azcoitia I, Garcia-Segura LM (2015) The neuroprotective actions of oestradiol and oestrogen receptors. *Nat Rev Neurosci* **16**, 17-29.
- [145] Rosario ER, Chang L, Head EH, Stanczyk FZ, Pike CJ (2011) Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease. *Neurobiol Aging* **32**, 604-613.
- [146] Genazzani AR, Pluchino N, Luisi S, Luisi M (2007) Estrogen, cognition and female ageing. *Hum Reprod Update* **13**, 175-187.
- [147] Cui J, Shen Y, Li R (2013) Estrogen synthesis and signaling pathways during aging: From periphery to brain. *Trends Mol Med* **19**, 197-209.
- [148] Brinton RD (2008) Estrogen regulation of glucose metabolism and mitochondrial function: Therapeutic implications for prevention of Alzheimer's disease. *Adv Drug Deliv Rev* **60**, 1504-1511.
- [149] Nielsen J, Brinton RD (2004) Mitochondria as therapeutic targets of estrogen action in the central nervous system. *Curr Drug Targets CNS Neurol Disord* **3**, 297-313.
- [150] Simpkins JW, Yang SH, Sarkar SN, Pearce V (2008) Estrogen actions on mitochondria—physiological and pathological implications. *Mol Cell Endocrinol* **290**, 51-59.
- [151] Engler-Chiurazzi EB, Brown CM, Povroznik JM, Simpkins JW (2016) Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury. *Prog Neurobiol*. doi: 10.1016/j.pneurobio.2015.12.008
- [152] Long J, He P, Shen Y, Li R (2012) New evidence of mitochondria dysfunction in the female Alzheimer's disease brain: Deficiency of estrogen receptor-beta. *J Alzheimers Dis* **30**, 545-558.
- [153] Zadori D, Klivenyi P, Szalardy L, Fulop F, Toldi J, Vecsei L (2012) Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: Novel therapeutic strategies for neurodegenerative disorders. *J Neurol Sci* **322**, 187-191.
- [154] Szalardy L, Klivenyi P, Zadori D, Fulop F, Toldi J, Vecsei L (2012) Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: Medicinal chemistry aspects. *Curr Med Chem* **19**, 1899-1920.
- [155] Torok N, Majlath Z, Fulop F, Toldi J, Vecsei L (2016) Brain aging and disorders of the central nervous system: Kynurenines and drug metabolism. *Curr Drug Metab* **17**, 412-429.

- 1335 [156] Zadori D, Veres G, Szalardy L, Klivenyi P, Toldi J, Vecsei L (2014) Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets. *J Alzheimers Dis* **42**(Suppl 3), S177-S187. 1360
- 1336 1361
- 1337 1362
- 1338 [157] Szalardy L, Zadori D, Klivenyi P, Toldi J, Vecsei L (2015) Electron transport disturbances and neurodegeneration: From Albert Szent-Gyorgyi's Concept (Szeged) till novel approaches to boost mitochondrial bioenergetics. *Oxid Med Cell Longev* **2015**, 498401. 1363
- 1339 1364
- 1340 1365
- 1341 1366
- 1342 1367
- 1343 [158] Koran ME, Wagener M, Hohman TJ, Alzheimer's Neuroimaging Initiative (2016) Sex differences in the association between AD biomarkers and cognitive decline. *Brain Imaging Behav*, doi: 10.1007/s11682-016-9523-8 1368
- 1344 1369
- 1345 [159] Rettberg JR, Yao J, Brinton RD (2014) Estrogen: A master regulator of bioenergetic systems in the brain and body. *Front Neuroendocrinol* **35**, 8-30. 1370
- 1346 1371
- 1347 [160] Golomb J, Kluger A, de Leon MJ, Ferris SH, Mittelman M, Cohen J, George AE (1996) Hippocampal formation size predicts declining memory performance in normal aging. *Neurology* **47**, 810-813. 1372
- 1348 1373
- 1349 [161] Jack CR Jr, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, Tangalos EG, Kokmen E (1998) Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. *Neurology* **51**, 993-999. 1374
- 1350 1375
- 1351 [162] Wang L, Swank JS, Glick IE, Gado MH, Miller MI, Morris JC, Csernansky JG (2003) Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging. *Neuroimage* **20**, 667-682. 1376
- 1352 1377
- 1353 [163] Ystad MA, Lundervold AJ, Wehling E, Espeseth T, Rootwelt H, Westlye LT, Andersson M, Adolfsdottir S, Geitung JT, Fjell AM, Reinvang I, Lundervold A (2009) Hippocampal volumes are important predictors for memory function in elderly women. *BMC Med Imaging* **9**, 17. 1378
- 1354 1379
- 1355 [164] Devanand DP, Bansal R, Liu J, Hao X, Pradhaban G, Peterson BS (2012) MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease. *Neuroimage* **60**, 1622-1629. 1380
- 1356 1381
- 1357 [165] Borghesani PR, Weaver KE, Aylward EH, Richards AL, Madhyastha TM, Kahn AR, Liang O, Ellenbogen RL, Beg MF, Schaie KW, Willis SL (2012) Midlife memory improvement predicts preservation of hippocampal volume in old age. *Neurobiol Aging* **33**, 1148-1155. 1382
- 1358 1383
- 1359 [166] Taki Y, Thyreau B, Kinomura S, Sato K, Goto R, Wu K, Kawashima R, Fukuda H (2013) A longitudinal study of age- and gender-related annual rate of volume changes in regional gray matter in healthy adults. *Hum Brain Mapp* **34**, 2292-2301. 1384
- 1385 [167] Crivello F, Tzourio-Mazoyer N, Tzourio C, Mazoyer B (2014) Longitudinal assessment of global and regional rate of grey matter atrophy in 1,172 healthy older adults: Modulation by sex and age. *PLoS One* **9**, e114478. 1385